Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the ...

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

Guidance on the new policy from the Department for Science, Innovation and Technology (DSIT) notes that qualifying for ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...